Skip to content

Living with sarcoma

Living with sarcoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON28169
Enrollment
1200
Registered
2018-05-28
Start date
2018-06-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcoma, cancer, survivorship, rare cancer. Sarcomen, kaker, overlevers, zeldzame kanker.

Interventions

None

Sponsors

Radboudumc
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: -Diagnosis of sarcoma sarcoma (according to the ICD-10-GM codes C40 and C41 for bone sarcoma and C49 for soft-tissue sarcoma), between 1/1/2008 and 31/12/2016. -Diagnosed or treated at one of participating centres (Radboud University Medical Centre Nijmegen, Erasmus Medical Centre Rotterdam, University Medical Centre Leiden, Netherlands Cancer Institute Amsterdam, University Medical Centre Groningen) -Must be able to complete questionnaire in Dutch

Exclusion criteria

Exclusion criteria: -Cognitive impairment -Too unwell to complete questionniare

Design outcomes

Primary

MeasureTime frame
•The health-related quality of life of sarcoma survivors (compared to age- and sex-matched normative population)

Secondary

MeasureTime frame
• Defining risk factors for a worse quality of life (compared to normative population): demographics, time to diagnosis and therapy, clinical characteristics (such as tumour type and site, type of treatment, progression/recurrence of disease), ability to work, financial difficulties, social support, psychological distress, information provision, body image, sexuality, ability to perform certain tasks (e.g. brush teeth, do groceries) • Assessing the body image (compared to normative population) • Assessing the psychological distress (compared to normative population) • Examining the level of certain symptoms (such as pain, fatigue, nausea) • Difference in HRQoL, body image, psychological distress, level of symptoms with regards to time since diagnosis • Assessing satisfaction with follow-up schedule • Assessing difficulties sarcoma patients encounter due to the rarity of the disease

Contacts

Public ContactVicky Soomers

Afdeling medische oncologie Radboudumc

Vicky.Soomers@radboudumc.nl0627209550

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)